
|Videos|January 8, 2021
C. Difficile Treatment: Bezlotoxumab
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Advertisement
Episodes in this series

Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Rapid HCV Test Provides Opportunity for Single Visit Diagnosis and Treatment Encounters
2
Phage and Antibiotic Combination Therapy for Biofilm-Associated Bacterial Infections
3
No Negative Impact for Individuals Taking Lenacapavir and Gender-Affirming Hormone Therapy
4
Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY Studies
5


























































































































































































































































































































